SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors react to the company securing significant clinical and regulatory milestones, including marketing approval in Japan, while maintaining a robust cash position without the immediate need for dilution. Community discussion is heavily focused on upcoming U.S. trial readouts and the potential for a broader valuation correction as analysts continue to issue optimistic price targets.

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is gaining significant community attention as a perceived beneficiary of the European natural gas crisis, with investors citing its critical infrastructure and low-float structure as potential catalysts for a squeeze. Traders are actively debating the upside of both the stock and its warrants amid ongoing geopolitical instability, with many highlighting its perceived value compared to other high-volatility oil and gas plays.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing significant market interest driven by growing anticipation surrounding a potential SpaceX IPO, which investors view as a broader validator for the satellite communications sector. The community is actively debating the company's long-term growth potential and execution roadmap while reacting to recent price volatility and institutional activity.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as retail investors rally behind its long-term potential in AI infrastructure and 6G development, often discussing the stock as a resilient, multi-thematic play despite recent market volatility. Discussion is heavily driven by its strategic partnerships with industry heavyweights like Nvidia, contract wins in defense and optical networking, and persistent institutional accumulation that has fueled bullish sentiment among long-term holders.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a significant analyst upgrade to a $40 price target, fueling speculation about the company's long-term potential as a best-in-class acquisition target for Big Pharma. Investors are closely monitoring upcoming Phase 3 trial data, with the community actively debating whether the company will secure a buyout or continue as an independent entity.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo Finance is attracting attention due to its strategic partnership with Franklin Templeton to tokenize traditional assets, fueling investor optimism about its role in bridging Wall Street with decentralized finance. While some in the community remain skeptical of recent price action, many actively discuss its long-term potential as a premier real-world asset (RWA) play.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple is currently a focal point for investors as they monitor potential progress on the U.S. Clarity Act, which many believe will provide the regulatory certainty needed to unlock significant institutional adoption and capital inflows. While market sentiment remains polarized, the community is actively debating the project's long-term utility versus its historical price volatility and the ongoing impact of broader macroeconomic pressures.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending as investors digest the strategic acquisition of StereoLabs, which consolidates lidar, camera, and AI perception software into a unified platform for the growing Physical AI market. While the stock faces broader market volatility, community discussion remains focused on the company's path to profitability, recent leadership commentary on future product releases, and its expanding footprint in defense, industrial automation, and smart infrastructure.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors focus on the potential for Rolvedon's market expansion, particularly through anticipated same-day dosing guidance, while the company maintains a strong cash position that currently exceeds its market capitalization. The community is actively debating the company's valuation gap, the strategic impact of potential divestitures, and whether leadership will pursue acquisitions or a sale of the company to unlock value for long-term shareholders.

Invesco CurrencyShares Euro Trust - Units of fractional undivided beneficial interest

Invesco CurrencyShares Euro Trust

Invesco CurrencyShares Euro Trust is attracting significant attention as traders analyze the potential for European Central Bank policy adjustments amid fluctuating energy costs and shifting U.S. interest rate expectations. The community is heavily focused on technical patterns and macro catalysts, weighing the impacts of regional geopolitical tensions against broader forex volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-one ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating...

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK

E. Ohman J or Asset Management AB lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 10.8% during the fourth quarter, according to its most recent filing with...

Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP lifted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 15.4% during the 3rd quarter, according to its most recent filing with the...

Cytokinetics (NASDAQ:CYTK) EVP Sells $530,885.30 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 8,542 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $530,885.30. Following the completion of the sale, the executive vice president...

Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Sung Lee sold 4,935 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $306,710.25. Following the sale, the executive vice president directly...

Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 1,930 shares of the firm's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $62.07, for a total value of $119,795.10. Following the completion of the sale, the executive vice...

Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 8,542 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $530,885.30. Following the completion of the sale, the...

Fady Ibraham Malik Sells 12,033 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 12,033 shares of Cytokinetics stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total value of $747,850.95. Following the sale, the executive...

Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert Blum sold 36,601 shares of the firm's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the sale, the chief executive officer...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CYTK News

CYTKCytokinetics Inc